ATE386049T1 - Epstein-barr virus type b ctl epitopen - Google Patents

Epstein-barr virus type b ctl epitopen

Info

Publication number
ATE386049T1
ATE386049T1 AT97921544T AT97921544T ATE386049T1 AT E386049 T1 ATE386049 T1 AT E386049T1 AT 97921544 T AT97921544 T AT 97921544T AT 97921544 T AT97921544 T AT 97921544T AT E386049 T1 ATE386049 T1 AT E386049T1
Authority
AT
Austria
Prior art keywords
barr virus
epstein
epitopes
epitopens
ctl
Prior art date
Application number
AT97921544T
Other languages
English (en)
Inventor
Rajiv Khanna
Beverley Kerr
Ihor Misko
Denis Moss
Scott Burrows
Original Assignee
Queensland Inst Med Res
Commw Scient Ind Res Org
Univ Melbourne
Inst Medical W & E Hall
Csl Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Queensland Inst Med Res, Commw Scient Ind Res Org, Univ Melbourne, Inst Medical W & E Hall, Csl Ltd filed Critical Queensland Inst Med Res
Application granted granted Critical
Publication of ATE386049T1 publication Critical patent/ATE386049T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
AT97921544T 1996-05-24 1997-05-23 Epstein-barr virus type b ctl epitopen ATE386049T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPO0073A AUPO007396A0 (en) 1996-05-24 1996-05-24 Ebv ctl epitopes

Publications (1)

Publication Number Publication Date
ATE386049T1 true ATE386049T1 (de) 2008-03-15

Family

ID=3794389

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97921544T ATE386049T1 (de) 1996-05-24 1997-05-23 Epstein-barr virus type b ctl epitopen

Country Status (8)

Country Link
EP (1) EP0906335B1 (de)
JP (1) JP2000511522A (de)
AT (1) ATE386049T1 (de)
AU (1) AUPO007396A0 (de)
CA (1) CA2255927A1 (de)
DE (1) DE69738512D1 (de)
GB (1) GB2332907B (de)
WO (1) WO1997045444A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO784197A0 (en) * 1997-07-10 1997-08-07 Csl Limited Treatment of nasopharyngeal carcinoma
ATE516045T1 (de) 2003-01-24 2011-07-15 Univ Massachusetts Medical Identifikation von vaccinia-virus-dominanten t- zell-epitopen
US8067535B2 (en) 2003-01-24 2011-11-29 The University Of Massachusetts Identification of gene sequences and proteins involved in vaccinia virus dominant T cell epitopes
CA2889064A1 (en) 2012-10-19 2014-04-24 The Council Of The Queensland Institute Of Medical Research Improved human herpesvirus immunotherapy
CN105555756B (zh) 2013-06-28 2018-12-07 奥克兰联合服务有限公司 氨基酸缀合物和肽缀合物及缀合方法
CN106794236B (zh) 2014-04-15 2021-09-03 格里菲斯大学 A群链球菌疫苗
US10253062B2 (en) * 2014-12-23 2019-04-09 Margaret Anne Brimble Amino acid and peptide conjugates and uses thereof
US11464853B2 (en) 2016-02-26 2022-10-11 Auckland Uniservices Limited Amino acid and peptide conjugates and conjugation process
MX2019002497A (es) 2016-09-02 2019-08-14 Univ James Cook Peptido con actividad para cicatrizacion de heridas.
KR102703633B1 (ko) 2016-11-09 2024-09-05 그리피스 유니버시티 서브틸라제 세포독소 b 서브유닛 돌연변이체
NL2023863B1 (en) 2019-09-20 2021-05-25 Univ Griffith Protein particles and uses thereof
JP7825273B2 (ja) 2019-11-25 2026-03-06 グリフィス ユニバーシティー 淋菌感染症に対する免疫原性タンパク質

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5374517A (en) * 1989-11-24 1994-12-20 Council Of The Queensland Institute Of Medical Research IM peptides
AUPM446594A0 (en) * 1994-03-16 1994-04-14 Csl Limited Cytotoxic t-cell epitopes identified within epstein-barr virus

Also Published As

Publication number Publication date
EP0906335A1 (de) 1999-04-07
GB9825551D0 (en) 1999-01-13
DE69738512D1 (de) 2008-03-27
GB2332907B (en) 2000-09-06
CA2255927A1 (en) 1997-12-04
EP0906335A4 (de) 2002-01-09
GB2332907A (en) 1999-07-07
WO1997045444A1 (en) 1997-12-04
EP0906335B1 (de) 2008-02-13
AUPO007396A0 (en) 1996-06-20
JP2000511522A (ja) 2000-09-05

Similar Documents

Publication Publication Date Title
FR20C1016I1 (de)
TR200202194T2 (tr) Poliglütamik asit-kamptotesin birleşikleri ve hazırlama yöntemleri
ATE418562T1 (de) Ctl epitope des epstein-barr virus
DK142391D0 (da) Indretning til tilberedning, servering og opbevaring af f.eks. madvarer
DE59807369D1 (de) Medizinische Bandage
NO20005672L (no) Svekkede Salmonella-mutanter som konstitutivt uttrykker Vi- antigenet
WO1998013500A3 (en) Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
NO20011162D0 (no) FremgangsmÕter og preparater for modulering av interaksjonen mellom APJ-reseptoren og HIV-viruset
DE69738512D1 (de) Epstein-barr virus type b ctl epitopen
GB2301591A (en) Cytotoxic T-cell epitopes
EP1147212A4 (de) T-helferzellen-epitope
NO983472D0 (no) Taxoider, deres fremstilling og farmas°ytiske preparater inneholdende taxoidene
FR2707297B1 (fr) Mélange silicone autoémulsifiable.
DE69725459D1 (de) Substituierte 1,2,3,4-tetrahydro-2-dibenzofuranamine und 2-aminocyclohepta(b)benzofurane
IL139604A0 (en) Novel peptides
DE3860354D1 (de) Neigungseinstell- und verstellvorrichtung fuer klapp-, lehnstuehle und aehnliche gegenstaende.
NO901483D0 (no) Gasstett innpakningsmateriale, fremgangsmaate til fremstilling av dette samt anvendelse av materialet.
DE69726602D1 (en) Hepatitis b inhibitoren
NO893835D0 (no) Sic-pulver, fremgangsmaate for fremstilling derav samt anvendelse av pulveret.
DE69105257D1 (de) Gasbrenner.
NO910590D0 (no) Hydratiserte silikater, fremgangsmaate for deres fremstilling og anvendelse.
DE69824881D1 (de) Kompakte replikons des epstein-barr-virus.
TR200103662T2 (tr) Yeni kalpainler ve bunların kullanılması
ZA200108398B (en) Anti-HIV-1 vaccine comprising all or part of the HIV-1 Tat protein.
DE69014100D1 (de) Cdns des orsv-virus gens.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties